MedTrace Logo

Rice Bran Supplementation in Treated HIV Infection

NCT02922907 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-04-29

No results posted yet for this study

Summary

Double-blind placebo-controlled randomized trial of Arabinoxylan Rice Bran Supplementation for 12 weeks with BRM4 in HIV-infected participants with inadequate immune reconstitution.

Conditions

  • Inflammation in HIV Infection

Interventions

DIETARY_SUPPLEMENT

arabinoxylan rice bran

a proprietary product derived from rice bran treated with extracts from three mushrooms

DIETARY_SUPPLEMENT

Placebo for arabinoxylan rice bran

inactive product

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Michael P Dubé, MD · University of Souther California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-24
Primary Completion
2018-12-03
Completion
2019-12-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922907 on ClinicalTrials.gov